VIRGINIA RETIREMENT SYSTEMS ET Al Sells 5,100 Shares of Charles River Laboratories International, Inc. $CRL

VIRGINIA RETIREMENT SYSTEMS ET Al lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 30.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,900 shares of the medical research company’s stock after selling 5,100 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Charles River Laboratories International were worth $3,511,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in shares of Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares in the last quarter. Bank of America Corp DE grew its position in Charles River Laboratories International by 5.0% in the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after purchasing an additional 54,500 shares in the last quarter. Amundi grew its position in Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after purchasing an additional 492,301 shares in the last quarter. Van Berkom & Associates Inc. grew its position in Charles River Laboratories International by 11.2% in the 1st quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock worth $86,449,000 after purchasing an additional 50,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Charles River Laboratories International by 230.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company’s stock valued at $59,044,000 after buying an additional 142,716 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $337.80 on Tuesday. The firm has a market cap of $16.13 billion, a price-to-earnings ratio of -69.65, a P/E/G ratio of 3.50 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a 52 week low of $146.20 and a 52 week high of $379.63. The firm’s 50-day simple moving average is $302.94 and its two-hundred day simple moving average is $222.94.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same period in the prior year, the firm earned $3.12 EPS. The company’s revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current year.

Wall Street Analyst Weigh In

CRL has been the topic of several recent analyst reports. Mizuho lifted their target price on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research note on Monday, August 10th. Deutsche Bank Aktiengesellschaft upped their target price on Charles River Laboratories International from $300.00 to $320.00 and gave the company a “buy” rating in a report on Friday, September 25th. Zacks Research raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Finally, Argus set a $330.00 price target on Charles River Laboratories International in a report on Thursday, September 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $302.33.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 2,156 shares of the firm’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,655,578.87. This trade represents a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 118,169 shares of company stock worth $35,191,216 in the last three months. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.